0001209191-19-039770.txt : 20190701 0001209191-19-039770.hdr.sgml : 20190701 20190701170119 ACCESSION NUMBER: 0001209191-19-039770 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190627 FILED AS OF DATE: 20190701 DATE AS OF CHANGE: 20190701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DOBMEIER ERIC CENTRAL INDEX KEY: 0001202785 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 19933948 MAIL ADDRESS: STREET 1: C/O SAETTLE GENETICS INC STREET 2: 21823 30TH DRIVE SE CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-27 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001202785 DOBMEIER ERIC C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2019-06-27 4 P 0 2000 19.50 A 16000 D Common Stock 2019-06-27 4 A 0 4000 0.00 A 20000 D Non-Qualified Stock Option (Right to Buy) 20.25 2019-06-27 4 A 0 13000 0.00 A 2029-06-26 Common Stock 13000 13000 D These restricted stock units shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. The option shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. /s/ David Tucker, Attorney-in-Fact 2019-07-01 EX-24.4_862744 2 poa.txt POA DOCUMENT POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Atara Biotherapeutics, Inc. (the "Company"), hereby constitutes and appoints Jeff Cislini, David Tucker, Nimit Arora, Mina Kim and Kim Merritt the undersigned's true and lawful attorneys-in-fact to: 1. Complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and 2. Do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate. The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended). This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. The undersigned hereby terminates all prior powers of attorney regarding the subject matter hereof. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of June 22, 2019. Signature: /s/ Eric L. Dobmeier Eric L. Dobmeier